Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE

A-423579
Names
	Preferred IUPAC name 4′-{3-[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]propoxy}-3′,5′-difluoro[1,1′-biphenyl]-4-carbonitrile
Identifiers
CAS Number	461045-17-0 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL498228 ;
ChemSpider	9524593 (R) ; 13210784 ;
PubChem CID	11349657 (R); 22994515;
UNII	Q2CW3V5WGF ;
CompTox Dashboard (EPA)	DTXSID90629426 ;
	InChI InChI=1S/C22H25F2N3O/c1-26(2)19-8-10-27(15-19)9-3-11-28-22-20(23)12-18(13-21(22)24)17-6-4-16(14-25)5-7-17/h4-7,12-13,19H,3,8-11,15H2,1-2H3/t19-/m1/s1 Key: DJXFZKXYKKBTDR-LJQANCHMSA-N ;
	SMILES CN(C)C1CCN(CCCOC2=C(F)C=C(C=C2F)C2=CC=C(C=C2)C#N)C1; CN(C)C1CCN(CCCOc2c(F)cc(cc2F):c2ccc(cc2)C#N)C1;
Properties
Chemical formula	C22H25F2N3O
Molar mass	385.4502 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H₃ subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.^[1]^[2]

References

^ Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (September 2004). "In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists". Basic & Clinical Pharmacology & Toxicology. 95 (3): 144–52. doi:10.1111/j.1742-7843.2004.950307.x. PMID 15447739.
^ Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (April 2005). "Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy". Inflammation Research. 54: S27–9. doi:10.1007/s00011-004-0412-z. PMID 15928821. S2CID 22094031.

[1] Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (September 2004). "In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists". Basic & Clinical Pharmacology & Toxicology. 95 (3): 144–52. doi:10.1111/j.1742-7843.2004.950307.x. PMID 15447739.

[2] Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (April 2005). "Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy". Inflammation Research. 54: S27–9. doi:10.1007/s00011-004-0412-z. PMID 15928821. S2CID 22094031.

[1]

[2]